American Legion Backs Veterans Psychedelics Bill in Congress

September 17, 2026

Photo by RDNE Stock project via Pexels.

Veterans organizations don't typically wade into drug scheduling fights. The American Legion just did anyway. At its 107th National Convention in Louisville, Kentucky, the group formally endorsed federal psychedelics legislation, putting the full weight of the nation's largest veterans organization -- 1.2 million members strong -- behind a bill that would build out psychedelic therapy infrastructure inside the Department of Veterans Affairs.

This isn't a fringe caucus or a handful of veteran-advocacy startups making noise on Capitol Hill. The Legion has posts in nearly every congressional district and a lobbying operation that lawmakers actually answer to. When an organization with that kind of institutional standing tells Congress to fund psilocybin and MDMA research for PTSD and traumatic brain injury, it changes how the issue gets talked about in committee rooms. The target of the endorsement is specific: S. 4220, the Veterans Health Administration's Novel Therapeutics Preparedness Act, a bill that already has co-sponsors from both parties and enough momentum that it cleared a Senate committee hearing earlier this year.

What the American Legion Resolution Actually Does

Photo by Luis Quintero via Pexels.

The resolution itself, titled Novel Therapeutics for Mental Health Conditions and Traumatic Brain Injury, was adopted as delegates wrapped up business at the Legion's national convention on September 4, 2026. It's a formal policy position, the kind of document that gets circulated to every congressional office the Legion's legislative division works with, and it directly names S. 4220 as the piece of legislation the organization wants passed.

What makes the resolution notable isn't its language so much as who's standing behind it. The American Legion counts more than 1.2 million dues-paying members, which gives it real lobbying muscle on Capitol Hill -- the kind that smaller psychedelic-advocacy nonprofits have never had access to. The resolution zeroes in on veterans dealing with PTSD, depression, and traumatic brain injury, three conditions that have proven stubbornly resistant to standard-issue VA treatment protocols for a lot of service members, and frames novel therapeutics research as a legitimate next step rather than an experiment.

The convention also elected a new National Commander, Jay Bowen of Colorado, who now leads the organization heading into a Congress that will decide whether S. 4220 gets a floor vote. Bowen inherits an organization that just staked out a position on psychedelics research that would have been unthinkable for a group with the Legion's establishment reputation a decade ago. That shift says as much about how veterans' mental health advocacy has evolved as it does about psychedelics themselves.

Inside S. 4220: The VA Office of Novel Therapeutics

S. 4220 is narrower than a lot of people assume. It doesn't legalize anything. What it does is create a dedicated VA Office of Novel Therapeutics, along with Centers of Excellence spread across each VA regional district, giving the agency a structural home for researching and eventually delivering these treatments rather than running scattered pilot programs.

The bill was introduced around late March 2026 by Sen. Tim Sheehy (R-MT), with Sens. Tammy Duckworth (D-Ill.), Ruben Gallego (D-Ariz.) and John Boozman (R-Ark.) signed on as co-sponsors -- a lineup that pairs two Republicans with two Democrats, which matters in a Congress where most drug policy bills split along predictable party lines. It also establishes a Veteran Advisory Committee made up of veterans, clinical experts, and health professionals tasked with identifying access barriers and shaping safety protocols before any treatment gets anywhere near widespread deployment.

Perhaps the most consequential provision is the coordination mandate. The bill requires the VA to work directly with HHS, the FDA, CMS, the Department of Defense, and the DEA on regulatory questions -- including the possibility of rescheduling certain substances and figuring out how insurance coverage would even work if these therapies move toward approval. Congress isn't left in the dark either: the legislation requires annual progress reports, giving lawmakers a built-in checkpoint to evaluate whether the office is delivering results. The Senate Veterans' Affairs Committee already held a hearing on the bill around April 29, 2026, a step that suggests this isn't sitting untouched in a drawer somewhere.

VA Leadership and the Push for Rescheduling

Photo by robinsonk26 via Pixabay.

VA Secretary Doug Collins addressed the Legion's convention directly, pointing to the agency's ongoing clinical trials into psychedelic therapies as a legitimate new avenue for treating veterans whose mental health conditions haven't responded to conventional care. Coming from the head of the VA rather than an outside advocate, that kind of statement carries weight -- it signals the agency itself sees this as a track worth pursuing, not just a political favor to a lobbying bloc.

The Legion hasn't stopped at endorsing S. 4220. Its leaders have separately pushed Congress to move psychedelic therapies from Schedule I to Schedule II under the Controlled Substances Act, a reclassification that wouldn't legalize these substances outright but would meaningfully ease the research restrictions that currently make studying them slow and expensive. Legion testimony to Congress has specifically flagged psilocybin, cannabis, ketamine, MDMA, and ibogaine as substances under active research for veteran mental health applications -- a list that spans plant-based compounds and synthetic ones, reflecting how broad the current research landscape actually is.

A Legion spokesperson named Mercer summed up the moment by describing the current alignment between veterans groups, Congress, and the VA as a rare opportunity, saying the goal now is to turn that momentum into lasting change. Rescheduling matters here because it's the hinge point: move these substances to Schedule II, and you open the door to easier clinical research and, down the line, a realistic path toward VA-covered treatment rather than access limited to small trial cohorts.

Years of Advocacy Behind One Bill

S. 4220 didn't materialize out of nowhere -- it's the latest step in a slow accumulation of federal action that's been building for a couple of years. Section 723 of the 2024 National Defense Authorization Act already authorized $10 million in grants for research into psychedelic and plant-based therapies, money that helped seed the clinical trials VA Secretary Collins referenced at the convention.

There's a companion effort moving through the House as well. Rep. Correa and Rep. Bergman have introduced the Innovative Therapies Centers of Excellence Act, which would direct $30 million annually toward funding five VA research centers focused specifically on psychedelics. Between the Senate and House versions, there's now a real bipartisan infrastructure push, not just a single bill riding on momentum from one advocacy cycle.

The sponsor list on S. 4220 -- two Republicans, two Democrats -- reflects something broader happening in drug policy right now: veterans' mental health has become one of the only corners of this debate where lawmakers from both parties are willing to move together without treating it as a culture-war flashpoint. That's a meaningfully different dynamic than the state-by-state fights over recreational cannabis or adult-use psilocybin decriminalization.

None of this changes the legal reality on the ground today, though. Federal law still classifies most of these substances as Schedule I, and legality for things like cannabis and psilocybin continues to vary widely state by state. Veterans dealing with PTSD or TBI shouldn't assume any of these therapies are currently accessible or legal to use outside approved research settings, and anyone considering treatment options should check their state's specific laws and talk to a qualified provider rather than assume federal momentum has already translated into access.

What the Legion brings to this fight is scale that psychedelics advocacy has never had before. A national organization with 1.2 million dues-paying members and posts in nearly every congressional district isn't easy for a member of Congress to wave off, especially when that organization is asking for research infrastructure rather than outright legalization. For lawmakers who've treated psychedelics reform as politically risky, the Legion's endorsement gives them cover -- this is now a veterans' health issue with an establishment stamp on it, not just a drug policy experiment.

It's worth being precise about what passage of S. 4220 would actually accomplish. It wouldn't legalize psychedelics broadly, and it wouldn't hand veterans immediate access to psilocybin or MDMA therapy at their local VA clinic. What it would do is build the research and treatment infrastructure -- the office, the regional centers, the advisory committee, the interagency coordination -- that has to exist before any of the bigger questions around scheduling and public access can even be seriously addressed. Those fights get left for later, in separate regulatory arenas.

The thing to watch now is whether the Senate Veterans' Affairs Committee actually moves S. 4220 to a floor vote before the current Congress runs out the clock. Bipartisan sponsorship and a high-profile endorsement don't guarantee survival once a bill hits the broader legislative logjam -- plenty of veterans' health measures with strong backing have stalled for reasons that have nothing to do with their merits. The Legion clearly understands this, which is likely why it's applying institutional pressure now rather than waiting to see how the vote count shakes out on its own.